Association of Single Measurements of Dipstick Proteinuria, Estimated Glomerular Filtration Rate, and Hematocrit with 25-Year Incidence of End-Stage Renal Disease in the Multiple Risk Factor Intervention Trial
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The incidence of ESRD is increasing rapidly. Limited information exists regarding early markers for the development of ESRD. This study aimed to determine over 25 yr the risk for ESRD associated with proteinuria, estimated GFR (eGFR), and hematocrit in men who did not have identified kidney disease and were randomly assigned into the Multiple Risk Factor Intervention Study (MRFIT). A total of 12,866 men who were at high risk for heart disease were enrolled (1973 to 1975) and followed through 1999. Renal replacement therapy was ascertained by matching identifiers with the United States Renal Data System's data; vital status was from the National Death Index. Men who initiated renal replacement therapy or died as a result of kidney disease were deemed to have developed ESRD. Dipstick urine for proteinuria, eGFR, and hematocrit were related to development of ESRD. During 25 yr, 213 (1.7%) men developed ESRD. Predictors of ESRD were dipstick proteinuria of 1+ or > or =2+ (hazard ratio [HR] 3.1 [95% confidence interval (CI) 1.8 to 5.4] and 15.7 [95% CI 10.3 to 23.9] respectively) and an eGFR of <60 ml/min per 1.73 m(2) (HR 2.4; 95% CI 1.5 to 3.8). Correlation between eGFR and serum creatinine was 0.9; the risk for ESRD with a 1-SD difference of each was identical (HR 1.21). Bivariate analysis demonstrated a 41-fold increase in ESRD risk in those with an eGFR <60 ml/min per 1.73 m(2) and > or =2+ proteinuria (95% CI 15.2 to 71.1). There was no association between hematocrit and ESRD. Other baseline measures that independently predicted ESRD included age, cigarette smoking, BP, low HDL cholesterol, and fasting glucose. Among middle-aged men who were at high risk for cardiovascular disease but had no clinical evidence of cardiovascular disease or significant kidney disease, dipstick proteinuria and an eGFR value <60 ml/min per 1.73 m(2) were strong predictors of long-term development of ESRD. It remains unknown whether intervention for proteinuria or early identification of those with chronic kidney disease reduces the risk for ESRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
Anavekar, N. S., McMurray, J. J. V., Velazquez, E. J., Solomon, S. D., Kober, L., Rouleau, J.-L., White, H. D., Nordlander, R., Maggioni, A., Dickstein, K., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041365 · Cited by 1,917
Blood Pressure and End-Stage Renal Disease in Men
Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. E., Shulman, N. B., & Stamler, J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340103 · Cited by 1,663
Self-citationGoodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Al-Ahmad, A., Rand, W. M., Manjunath, G., Konstam, M. A., Salem, D. N., Levey, A. S., & Sarnak, M. J. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01470-x · Cited by 701
End-stage renal disease in African-American and white men. 16-year MRFIT findings
Klag, M. J. (1997) · JAMA · doi:10.1001/jama.277.16.1293 · Cited by 612
Proteinuria and the risk of developing end-stage renal disease
Iseki, K., Ikemiya, Y., Iseki, C., & Takishita, S. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00868.x · Cited by 566
Keane, W. F., Brenner, B. M., de Zeeuw, D., Grunfeld, J.-P., McGill, J., Mitch, W. E., Ribeiro, A. B., Shahinfar, S., Simpson, R. L., Snapinn, S. M., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00885.x · Cited by 539
Haroun, M. K., Jaar, B. G., Hoffman, S. C., Comstock, G. W., Klag, M. J., & Coresh, J. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000095249.99803.85 · Cited by 532
Sarnak, M. J., Greene, T., Wang, X., Beck, G., Kusek, J. W., Collins, A. J., & Levey, A. S. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-5-200503010-00009 · Cited by 521
Self-citationThe prognostic significance of proteinuria: The Framingham study
Kannel, W. B., Stampfer, M. J., Castelli, W. P., & Verter, J. (1984) · American Heart Journal · doi:10.1016/0002-8703(84)90763-4 · Cited by 377
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
Jafar, T. H., Stark, P. C., Schmid, C. H., Landa, M., Maschio, G., Marcantoni, C., De Jong, P. E., De Zeeuw, D., Shahinfar, S., Ruggenenti, P., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.0600031131.x · Cited by 377
Blood Pressure Predicts Risk of Developing End-Stage Renal Disease in Men and Women
Tozawa, M., Iseki, K., Iseki, C., Kinjo, K., Ikemiya, Y., & Takishita, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000069699.92349.8c · Cited by 352
Early Predictors of 15-Year End-Stage Renal Disease in Hypertensive Patients
Perry, H. M., Miller, J. P., Fornoff, J. R., Baty, J. D., Sambhi, M. P., Rutan, G., Moskowitz, D. W., & Carmody, S. E. (1995) · Hypertension · doi:10.1161/01.hyp.25.4.587 · Cited by 347
Risk of developing end-stage renal disease in a cohort of mass screening
Iseki, K., Iseki, C., Ikemiya, Y., & Fukiyama, K. (1996) · Kidney International · doi:10.1038/ki.1996.111 · Cited by 342
The role of proteinuria in the progression of chronic renal failure
Burton, C., & Harris, K. P. G. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90512-0 · Cited by 316
Surrogate Markers for Cardiovascular Disease: Functional Markers
Cohn, J. N., Quyyumi, A. A., Hollenberg, N. K., & Jamerson, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000133442.99186.39 · Cited by 284
Brancati, F. L. (1997) · JAMA · doi:10.1001/jama.278.23.2069 · Cited by 272
Wentworth, D. N., Neaton, J. D., & Rasmussen, W. L. (1983) · American Journal of Public Health · doi:10.2105/ajph.73.11.1270 · Cited by 222
Self-citationProteinuria and blood pressure as causal components of progression to end-stage renal failure
Locatelli, F., Marcelli, D., Comelli, M., Alberti, D., Graziani, G., Buccianti, G., Redaelli, B., Giangrande, A., & Italy the Northern Italian Cooperative Study Group (1996) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/11.3.461 · Cited by 191
The multiple risk factor intervention trial (MRFIT) II. The development of the protocol.
Sherwin, R., Kaelber, C., Kezdi, P., Kjelsberg, M. O., & Thomas, H. (1981) · Preventive Medicine · doi:10.1016/0091-7435(81)90058-x · Cited by 188
Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT)
Neaton, J. D., Grimm, R. H., & Cutler, J. A. (1987) · Controlled Clinical Trials · doi:10.1016/0197-2456(87)90006-7 · Cited by 87
Self-citationHeart-Kidney Interactions in Ischemic Syndromes
Andreotti, F., Crea, F., & Conti, E. (2004) · Circulation · doi:10.1161/01.cir.0000115207.45378.bc · Cited by 72
Dischinger, P. C., & DuChene, A. G. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90164-9 · Cited by 60
Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies
Ruggenenti, P., Perna, A., Mosconi, L., Matalone, M., Pisoni, R., Gaspari, F., & Remuzzi, G. (1997) · Kidney International · Cited by 50
Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial
Eberly, L. E., Neaton, J. D., Thomas, A. J., & Dai, Y. (2004) · Clinical Trials · doi:10.1191/1740774504cn018oa · Cited by 31
Self-citationWiddowson, G. M., Kuehneman, M., DuChene, A. G., Hulley, S. B., & Cooper, G. R. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90157-1 · Cited by 21
Cited by
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
van der Velde, M., the Chronic Kidney Disease Prognosis Consortium, Matsushita, K., Coresh, J., Astor, B. C., Woodward, M., Levey, A. S., de Jong, P. E., & Gansevoort, R. T. (2011) · Kidney International · doi:10.1038/ki.2010.536 · Cited by 1,082
Matsushita, K., Mahmoodi, B. K., Woodward, M., Emberson, J. R., Jafar, T. H., Jee, S. H., Polkinghorne, K. R., Shankar, A., Smith, D. H., Tonelli, M., et al. (2012) · JAMA · doi:10.1001/jama.2012.3954 · Cited by 988
Gansevoort, R. T., Matsushita, K., van der Velde, M., Astor, B. C., Woodward, M., Levey, A. S., de Jong, P. E., & Coresh, J. (2011) · Kidney International · doi:10.1038/ki.2010.531 · Cited by 883
Metadata
- Authors
- Ishani, A., Grandits, G. A., Grimm, R. H., Svendsen, K. H., Collins, A. J., Prineas, R. J., & Neaton, J. D.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-05
- Volume
- 17
- Issue
- 5
- Pages
- 1444-1452
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2159843374
- Cited by
- 272
- References
- 30
- FWCI
- 10.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.